Atlas Trials

Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance

Clinical trial NCT07209371 · RECRUITING

Trial details

NCT number
NCT07209371
Sponsor
Fred Hutchinson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
IgA Monoclonal Gammopathy of Undetermined SignificanceNon-IgM Monoclonal Gammopathy of Undetermined Significance
Start date
2026-01-22
Primary completion
2028-05-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.